Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 17;29(3):2064-2072.
doi: 10.3390/curroncol29030166.

Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada

Ceilidh MacPhail  1 , Stephanie Snow  1
Affiliations
Review

Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada

Ceilidh MacPhail et al. Curr Oncol. .

Abstract

Canada lacks a national drug insurance plan. The home province or territory of a patient determines which cancer drugs are available on the public formulary, who is eligible for public coverage and what portion of the financial burden of cancer care falls to the individual. This narrative review describes the current interprovincial disparities in access to cancer drugs across Canada. Health technology assessment (HTA) of drugs at a provincial and territory level is a closed process, does not necessarily follow the recommendations of national HTA and leads to further delays in drug access. The public coverage of take-home cancer drugs (THCDs) in Ontario and the Atlantic provinces is often fragmented, unnecessarily complex and a barrier to cancer drug access. Policy solutions to address inter-provincial formulary variation and poor access to THCDs are discussed.

Keywords: Canada; drug funding; oncology; universal health care.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Institutions involved in drug assessment and addition to public formulary in Canada.
See this image and copyright information in PMC

References

    1. Menon D., Stafinski T., Stuart G. Access to Drugs for Cancer. Can. J. Public Health. 2005;96:454–458. doi: 10.1007/BF03405189. - DOI - PMC - PubMed
    1. Abdel-Rahman O., North S. Patterns of cost-related medication underuse among Canadian adults with cancer: A cross-sectional study using survey data. CMAJ Open. 2021;9:E474–E481. doi: 10.9778/cmajo.20200186. - DOI - PMC - PubMed
    1. Demers V., Melo M., Jackevicius C., Cox J., Kalavrouziotis D., Rinfret S., Humphries K.H., Johansen H., Tu J.V., Pilote L. Comparison of provincial prescription drug plans and the impact on patients’ annual drug expenditures. Can. Med. Assoc. J. 2008;178:405–409. doi: 10.1503/cmaj.070587. - DOI - PMC - PubMed
    1. Longo C.J., Fitch M.I., Loree J.M., Carlson L.E., Turner D., Cheung W.Y., Gopaul D., Ellis J., Ringash J., Mathews M., et al. Patient and Family Financial Burden Associated with Cancer Treatment in Canada: A National Study. Support. Care Cancer. 2021;29:3377–3386. doi: 10.1007/s00520-020-05907-x. - DOI - PMC - PubMed
    1. Lung Cancer Canada . Faces of Lung Cancer. Lung Cancer Canada; Toronto, ON, Canada: 2019.

Substances